Response to Sistermans et al
- PMID: 31680122
- DOI: 10.1038/s41436-019-0687-7
Response to Sistermans et al
Comment on
-
Outcomes in pregnancies with a confined placental mosaicism and implications for prenatal screening using cell-free DNA.Genet Med. 2020 Feb;22(2):309-316. doi: 10.1038/s41436-019-0630-y. Epub 2019 Aug 8. Genet Med. 2020. PMID: 31391534
-
The clinical benefit of genome-wide cfDNA testing cannot be extrapolated from CVS data.Genet Med. 2020 Mar;22(3):657-658. doi: 10.1038/s41436-019-0689-5. Epub 2019 Nov 6. Genet Med. 2020. PMID: 31690836 No abstract available.
References
-
- Sistermans EA, Van Opstal D, Bekker MN, Pertile MD. The clinical benefit of genome-wide cfDNA testing cannot be extrapolated from CVS data. Genet Med. (in press).
-
- Grati FR, Ferreira J, Benn P, et al. Outcomes in pregnancies with a confined placental mosaicism and implications for prenatal screening using cell-free DNA. Genet Med. 2019 Aug 8; https://doi.org/10.1038/s41436-019-0630-y . [Epub ahead of print]. - DOI
-
- Benn P, Malvestiti F, Grimi B, et al. Rare autosomal trisomies: comparison of detection through cell-free DNA analysis and direct chromosome preparation of chorionic villus samples. Ultrasound Obstet Gynecol. 2019;54:458–467. - DOI
-
- Brison N, Neofytou M, Dehaspe L, et al. Predicting fetoplacental chromosomal mosaicism during non-invasive prenatal testing. Prenat Diagn. 2018;38:258–266. - DOI
-
- Taylor TH, Gitlin SA, Patrick JL, et al. The origin, mechanisms, incidence and clinical consequences of chromosomal mosaicism in humans. Hum Reprod Update. 2014;20:571–581. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources